uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
uniQure BV (QURE) PT Raised to $72 at B.Riley/FBR
November 15, 2018 9:58 AM ESTB.Riley/FBR analyst Madhu Kumar raised the price target on uniQure BV (NASDAQ: QURE) to $72.00 (from $50.00) while maintaining a Buy rating.
... MoreuniQure BV (QURE) PT Raised to $65 at Cantor Fitzgerald
November 15, 2018 9:36 AM ESTCantor Fitzgerald analyst Elemer Piros raised the price target on uniQure BV (NASDAQ: QURE) to $65.00 (from $58.00) while maintaining a Overweight rating.
Piros commented, "This morning, uniQure announced initial top-line data from the Phase 2b dose-confirmation study of AMT-061 for the treatment of... More
uniQure BV (QURE) PT Raised to 'Street High' $76 at Leerink Partners
November 15, 2018 8:56 AM ESTLeerink Partners analyst Joseph Schwartz raised the price target on uniQure BV (NASDAQ: QURE) to a 'Street High' $76.00 (from $61.00) while maintaining an Outperform rating following AMT-061 data.
... MoreuniQure (QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
November 15, 2018 7:20 AM ESTuniQure (NASDAQ: QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
... More